In Q3, biopharma financing totaled $7.4 billion, a large proportion of which was by rare disease developers; among the highlights in the $23 billion in m&as was allergan’s buying spree, including two nash companies. Just over $20 billion went into biopharma alliance dealmaking, and neurology assets attracted many of the dollars.
EXECUTIVE SUMMARY
In Q3, biopharma financing totaled $7.4 billion, a large proportion of which was by rare disease developers; among the highlights in the $23 billion in m&as was allergan’s buying spree, including two nash companies. Just over $20 billion went into biopharma alliance dealmaking, and neurology assets attracted many of the dollars.
Exhibit 1: Q3 2016 Biopharma Financing: $ raised